231 related articles for article (PubMed ID: 21973229)
1. Clinical utility of ADHD symptom thresholds to assess normalization of executive function with lisdexamfetamine dimesylate treatment in adults.
Brown TE; Brams M; Gasior M; Adeyi B; Babcock T; Dirks B; Scheckner B; Wigal T
Curr Med Res Opin; 2011; 27 Suppl 2():23-33. PubMed ID: 21973229
[TBL] [Abstract][Full Text] [Related]
2. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults.
Brown TE; Brams M; Gao J; Gasior M; Childress A
Postgrad Med; 2010 Sep; 122(5):7-17. PubMed ID: 20861583
[TBL] [Abstract][Full Text] [Related]
3. Effect size of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Wigal T; Brams M; Gasior M; Gao J; Giblin J
Postgrad Med; 2011 Mar; 123(2):169-76. PubMed ID: 21474905
[TBL] [Abstract][Full Text] [Related]
4. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
Findling RL; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; DeLeon A; Ginsberg LD
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):28-35. PubMed ID: 23410139
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with attention-deficit/hyperactivity disorder stratified by baseline severity.
Ginsberg L; Katic A; Adeyi B; Dirks B; Babcock T; Lasser R; Scheckner B; Adler LA
Curr Med Res Opin; 2011 Jun; 27(6):1097-107. PubMed ID: 21438796
[TBL] [Abstract][Full Text] [Related]
8. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study.
Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH
J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447
[TBL] [Abstract][Full Text] [Related]
9. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
Weisler RH; Babcock T; Adeyi B; Brams M
Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
11. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
12. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder previously treated with amphetamines: analyses from a randomized, double-blind, multicenter, placebo-controlled titration study.
Babcock T; Dirks B; Adeyi B; Scheckner B
BMC Pharmacol Toxicol; 2012 Dec; 13():18. PubMed ID: 23254273
[TBL] [Abstract][Full Text] [Related]
14. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD.
Brams M; Giblin J; Gasior M; Gao J; Wigal T
Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
16. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD.
Brown TE; Landgraf JM
Postgrad Med; 2010 Sep; 122(5):42-51. PubMed ID: 20861587
[TBL] [Abstract][Full Text] [Related]
17. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial.
Childress AC; Arnold V; Adeyi B; Dirks B; Babcock T; Scheckner B; Lasser R; Lopez FA
J Atten Disord; 2014 Feb; 18(2):123-32. PubMed ID: 22740112
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments.
Katic A; Dirks B; Babcock T; Scheckner B; Adeyi B; Richards C; Findling RL
J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):386-93. PubMed ID: 23952185
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Findling RL; Ginsberg LD; Jain R; Gao J
J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):649-62. PubMed ID: 20035583
[TBL] [Abstract][Full Text] [Related]
20. Self-Reported quality of life in adults with attention-deficit/hyperactivity disorder and executive function impairment treated with lisdexamfetamine dimesylate: a randomized, double-blind, multicenter, placebo-controlled, parallel-group study.
Adler LA; Dirks B; Deas P; Raychaudhuri A; Dauphin M; Saylor K; Weisler R
BMC Psychiatry; 2013 Oct; 13():253. PubMed ID: 24106804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
